Treatment for Periorbital Cellulitis Linked to Herpes Zoster Ophthalmicus

Antiviral Therapy

The American Academy of Ophthalmology recommends oral antiviral therapy, such as valacyclovir 1000 mg three times daily for 7 days, for the treatment of periorbital cellulitis associated with herpes zoster ophthalmicus (HZO) in immunocompetent adults 1, 2, 3
Acyclovir 800 mg five times daily for 7 days and famciclovir 500 mg three times daily for 7 days are also recommended oral antiviral regimens for HZO-related periorbital cellulitis 1, 2
Patients with chronic or recalcitrant disease may require prolonged treatment with dose adjustments based on clinical response, with a strength of evidence supporting the use of oral antivirals 2, 3
Immunocompromised patients may need more aggressive antiviral therapy, with a moderate strength of evidence supporting the use of oral antivirals 1, 3

Topical antibiotics are recommended to prevent secondary bacterial infection of vesicles that undergo necrosis before healing, with a high strength of evidence supporting their use 1, 4
Secondary bacterial infection can lead to severe complications, including cicatricial ectropion, with a moderate strength of evidence supporting the use of topical antibiotics 2, 4

Topical antivirals alone have not been shown to be helpful in treating VZV conjunctivitis, with a low strength of evidence supporting their use 1, 4
Ganciclovir 0.15% gel and trifluridine 1% solution may be used as additive treatment in unresponsive patients, with a moderate strength of evidence supporting their use 1, 2

Caution is advised when using systemic antiviral therapy in patients with impaired renal clearance, with a high strength of evidence supporting dose adjustments 3
Topical corticosteroids should be avoided in epithelial viral infections as they can potentiate the infection, with a moderate strength of evidence supporting their avoidance 1, 2
Monitor for potential ocular complications of HZO, including pseudodendrites, keratitis, corneal scarring, corneal vascularization, iritis/uveitis, sectoral iris atrophy, and secondary glaucoma, with a moderate strength of evidence supporting monitoring 2, 3

Patients should have a follow-up visit within 1 week of treatment initiation, with a high strength of evidence supporting follow-up 1, 2
The follow-up should include interval history, visual acuity measurement, and slit-lamp biomicroscopy, with a moderate strength of evidence supporting these assessments 1, 2, 3

Late sequelae of HZO may include dry eye and corneal anesthesia with neurotrophic keratitis, requiring ongoing monitoring, with a moderate strength of evidence supporting monitoring 2, 3

For inflammatory complications without epithelial disease, corticosteroids may be considered under ophthalmologist supervision 5
In cases with subepithelial infiltrates causing blurring, photophobia, and decreased vision, topical corticosteroids at the minimum effective dose may be considered 5

Intraocular pressure measurement is recommended if the patient is on corticosteroid therapy 5

Apply topical antibiotics to vesicular lesions to prevent secondary bacterial infection, which can lead to severe complications, according to the American Academy of Ophthalmology 6
Topical antivirals alone have not been shown to be helpful in treating varicella zoster virus conjunctivitis and should not be used as monotherapy, as recommended by the American Academy of Ophthalmology 6

Topical corticosteroids must be avoided during active epithelial viral infection as they potentiate viral replication and worsen the infection, according to the American Academy of Ophthalmology 6
Corticosteroids may only be considered for inflammatory complications without epithelial disease and must be under direct ophthalmologist supervision, with preference for poor ocular penetration formulations to minimize risk of elevated intraocular pressure and cataract formation, as recommended by the American Academy of Ophthalmology 6

Schedule follow-up within 1 week of treatment initiation including interval history, visual acuity measurement, and slit-lamp biomicroscopy, according to the American Academy of Ophthalmology 6
For patients on corticosteroid therapy, monitor intraocular pressure regularly and perform pupillary dilation to evaluate for glaucoma and cataract, as recommended by the American Academy of Ophthalmology 6

The Centers for Disease Control and Prevention strongly recommend recombinant zoster vaccine for all immunocompetent patients aged 50 years and older to prevent herpes zoster and its complications, with 96% efficacy, according to the American Academy of Ophthalmology 7